Stock Track | PTC Therapeutics Plummets 5.14% Intraday After Earnings Miss and RBC Price Target Cut

Stock Track

Yesterday

PTC Therapeutics Inc. (PTCT) shares plummeted 5.14% during intraday trading on Friday, following the release of disappointing quarterly results and a downward revision of its price target by a major analyst firm.

The biopharmaceutical company reported a significant earnings miss for the quarter ended December 31, posting an adjusted loss of $1.67 per share. This result fell far short of the mean analyst estimate for a profit of $0.04 per share. Furthermore, revenue of $213.20 million missed expectations of $276.66 million, and the company reported a quarterly loss of $134.97 million.

Adding to the negative sentiment, RBC Capital maintained its Sector Perform (Hold) rating on the stock but cut its price target to $82 from $87. The analyst action, citing the recent earnings performance, contributed to the selling pressure on PTC Therapeutics shares during the trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1117089655"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117089655\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1117089655?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 23:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117089655","market":"us","top_or_hot":-1,"title":"Stock Track | PTC Therapeutics Plummets 5.14% Intraday After Earnings Miss and RBC Price Target Cut","media":"Stock Track","content":"<p>PTC Therapeutics Inc. (PTCT) shares plummeted 5.14% during intraday trading on Friday, following the release of disappointing quarterly results and a downward revision of its price target by a major analyst firm.</p><p>The biopharmaceutical company reported a significant earnings miss for the quarter ended December 31, posting an adjusted loss of $1.67 per share. This result fell far short of the mean analyst estimate for a profit of $0.04 per share. Furthermore, revenue of $213.20 million missed expectations of $276.66 million, and the company reported a quarterly loss of $134.97 million.</p><p>Adding to the negative sentiment, RBC Capital maintained its Sector Perform (Hold) rating on the stock but cut its price target to $82 from $87. The analyst action, citing the recent earnings performance, contributed to the selling pressure on PTC Therapeutics shares during the trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PTC Therapeutics Plummets 5.14% Intraday After Earnings Miss and RBC Price Target Cut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PTC Therapeutics Plummets 5.14% Intraday After Earnings Miss and RBC Price Target Cut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-20 23:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PTC Therapeutics Inc. (PTCT) shares plummeted 5.14% during intraday trading on Friday, following the release of disappointing quarterly results and a downward revision of its price target by a major analyst firm.</p><p>The biopharmaceutical company reported a significant earnings miss for the quarter ended December 31, posting an adjusted loss of $1.67 per share. This result fell far short of the mean analyst estimate for a profit of $0.04 per share. Furthermore, revenue of $213.20 million missed expectations of $276.66 million, and the company reported a quarterly loss of $134.97 million.</p><p>Adding to the negative sentiment, RBC Capital maintained its Sector Perform (Hold) rating on the stock but cut its price target to $82 from $87. The analyst action, citing the recent earnings performance, contributed to the selling pressure on PTC Therapeutics shares during the trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTCT","symbol_name":"PTC Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1117089655","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117089655","pubTimestamp":1771600479,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PTC Therapeutics Inc. (PTCT) shares plummeted 5.14% during intraday trading on Friday, following the release of disappointing quarterly results and a downward revision of its price target by a major...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTCT":"PTC Therapeutics Inc."},"translate_title":"个股追踪|PTC Therapeutics盘中暴跌5.14%，此前盈利未达预期且RBC目标价下调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTCT":1},"content_text":"PTC Therapeutics Inc. (PTCT) shares plummeted 5.14% during intraday trading on Friday, following the release of disappointing quarterly results and a downward revision of its price target by a major analyst firm.The biopharmaceutical company reported a significant earnings miss for the quarter ended December 31, posting an adjusted loss of $1.67 per share. This result fell far short of the mean analyst estimate for a profit of $0.04 per share. Furthermore, revenue of $213.20 million missed expectations of $276.66 million, and the company reported a quarterly loss of $134.97 million.Adding to the negative sentiment, RBC Capital maintained its Sector Perform (Hold) rating on the stock but cut its price target to $82 from $87. The analyst action, citing the recent earnings performance, contributed to the selling pressure on PTC Therapeutics shares during the trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}